MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Chloroquine phosphate

CAS No. : 50-63-5

MCE 站：Chloroquine phosphate

产品活性：Chloroquine phosphate 是一种广泛用于疟疾和类风湿性关节炎的抗疟疾和抗炎剂。Chloroquine phosphate 是 autophagy 和 toll-like receptors (TLRs) 的抑制剂。Chloroquine phosphate 有效抑制 SARS-CoV-2 (COVID-19) 感染 (EC₅₀=1.13 μM)。

研究领域：Autophagy  |  Immunology/Inflammation  |  Anti-infection

作用靶点：Parasite  |  Autophagy  |  SARS-CoV  |  Toll-like Receptor (TLR)  |  HIV  |  Antibiotic

In Vitro: Chloroquine (CHQ, 20 μM) inhibits IL-12p70 release and reduces Th1-priming capacity of activated human monocyte-derived Langerhans-like cells (MoLC). Chloroquine (CHQ, 20 μM) enhances IL-1–induced IL-23 secretion in MoLC and subsequently increases IL-17A release by primed CD4⁺ T cells. Chloroquine (25 μM) suppresses MMP-9 mRNA expression in normoxia and hypoxia in parental MDA-MB-231 cells. Chloroquine has cell-, dose- and hypoxia-dependent effects on MMP-2, MMP-9 and MMP-13 mRNA expression. TLR7 and TLR9 inhibition using IRS-954 or chloroquine significantly reduces HuH7 cell proliferation in vitro.
Chloroquine (0.01-100 μM; 48?hours) potently blocks virus infection (vero E6 cells infected with SARS-CoV-2) at low-micromolar concentration (EC₅₀=?1.13?μM). Chloroquine blocks virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.

In Vivo: Chloroquine (80 mg/kg, i.p.) does not prevent the growth of the triple-negative MDA-MB-231 cells with high or low TLR9 expression levels in the orthotopic mouse model. TLR7 and TLR9 inhibition using IRS-954 or chloroquine significantly inhibits tumour growth in the mouse xenograft model. HCC development in the DEN/NMOR rat model is also significantly inhibited by chloroquine.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Autophagy Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Drug Repurposing Compound Library  |  Antioxidants Compound Library  |  Differentiation Inducing Compound Library  |  Oxygen Sensing Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Pyroptosis Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Antibiotics Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Rapamycin  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Puromycin dihydrochloride  |  Cycloheximide  |  Chloroquine  |  Resatorvid  |  5-Fluorouracil  |  Staurosporine  |  Dexamethasone  |  Doxycycline (hyclate)  |  Actinomycin D  |  Cyclosporin A  |  G-418 disulfate  |  5-Azacytidine  |  Etoposide  |  Mitomycin C  |  Nigericin sodium salt  |  Brefeldin A  |  Wortmannin  |  Resveratrol  |  Resiquimod  |  Tunicamycin  |  Bleomycin sulfate  |  Hygromycin B  |  Hydroxychloroquine sulfate  |  Tacrolimus  |  Ionomycin  |  Favipiravir  |  Valproic acid

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。